PubMed

Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.

Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE.

Diabetes Care. 2003 Jun;26(6):1685-90.PMID: 12766094 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.

Horton ES, Foley JE, Shen SG, Baron MA.

Curr Med Res Opin. 2004 Jun;20(6):883-9.PMID: 15200747 [PubMed - indexed for MEDLINE]Related articles

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S.

Diabetes Care. 2000 Nov;23(11):1660-5.PMID: 11092289 [PubMed - indexed for MEDLINE]Related articlesFree article

Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.

Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE.

Diabetes Care. 2001 Jun;24(6):983-8.PMID: 11375357 [PubMed - indexed for MEDLINE]Related articlesFree article

A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM; Repaglinide Versus Nateglinide Comparison Study Group.

Diabetes Care. 2004 Jun;27(6):1265-70.PMID: 15161773 [PubMed - indexed for MEDLINE]Related articlesFree article

Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

Hanefeld M, Bouter KP, Dickinson S, Guitard C.

Diabetes Care. 2000 Feb;23(2):202-7.PMID: 10868832 [PubMed - indexed for MEDLINE]Related articlesFree article

Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).

Gribble FM, Manley SE, Levy JC.

Diabetes Care. 2001 Jul;24(7):1221-5.PMID: 11423506 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.

Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D.

J Clin Endocrinol Metab. 2002 Sep;87(9):4171-6.PMID: 12213867 [PubMed - indexed for MEDLINE]Related articlesFree article

Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes.

Rosenstock J, Shen SG, Gatlin MR, Foley JE.

Diabetes Care. 2002 Sep;25(9):1529-33.PMID: 12196422 [PubMed - indexed for MEDLINE]Related articlesFree article

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Roberts VL, Stewart J, Issa M, Lake B, Melis R.

Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

J Clin Pharm Ther. 2009 Feb;34(1):13-23.PMID: 19125899 [PubMed - indexed for MEDLINE]Related articles

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

Clin Ther. 2005 Aug;27(8):1181-95.PMID: 16199244 [PubMed - indexed for MEDLINE]Related articles

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM; Repaglinide vs. Nateglinide Metformin Combination Study Group.

Diabetes Care. 2003 Jul;26(7):2063-8. Erratum in: Diabetes Care. 2003 Sep;26(9):2708. PMID: 12832314 [PubMed - indexed for MEDLINE]Related articlesFree article

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

Clin Ther. 2005 May;27(5):554-67.PMID: 15978304 [PubMed - indexed for MEDLINE]Related articles

Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.

Marre M, Van Gaal L, Usadel KH, Ball M, Whatmough I, Guitard C.

Diabetes Obes Metab. 2002 May;4(3):177-86.PMID: 12047396 [PubMed - indexed for MEDLINE]Related articles

Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

Hirschberg Y, Karara AH, Pietri AO, McLeod JF.

Diabetes Care. 2000 Mar;23(3):349-53.PMID: 10868864 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group.

Clin Ther. 2006 Oct;28(10):1556-68.PMID: 17157112 [PubMed - indexed for MEDLINE]Related articles

Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.

Campbell IW.

Int J Clin Pract. 2005 Oct;59(10):1218-28. Review.PMID: 16178991 [PubMed - indexed for MEDLINE]Related articles